Mumps News and Research

RSS

Mumps is a viral disease characterized by fever, headache, muscle weakness, stiff neck, loss of appetite, swelling and tenderness of one or more of the salivary glands situated along the angle of the jaw and inside the mouth, including the parotid gland located within the cheeks just below the front of the ear.

Sinovac Beijing expands production capacity with acquisition of buildings and land use rights in Changping

Sinovac Biotech Ltd. (SVA), a leading China-based vaccine manufacturer, today announced the completion by its subsidiary, Sinovac Beijing, of the acquisition of buildings and land use rights. The total consideration for the purchase is approximately RMB120 million ($17.6 million), which will be financed from working capital. The initial payment of RMB56.5 million ($8.3 million) will be paid before February 20, 2010 and the balance of the purchase price will be paid in three installments within three years.

16 Feb 2010

Measles vaccine does not increase risk of autism in children, reveals Polish study

As a pivotal paper linking childhood vaccinations to autism is discredited, a new study finds no evidence that the measles vaccine—given alone or as part of a combined measles, mumps, and rubella (MMR) vaccine—increases the risk of autism in children. The study appears in The Pediatric Infectious Disease Journal (www.pidj.com), published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

10 Feb 2010

Expert available to discuss Lancet’s retraction of paper on autism study

Rae Sonnenmeier, clinical associate professor of communication sciences and disorders at the University of New Hampshire and staff member at UNH's Institute on Disability, is available to discuss the announcement yesterday (Feb. 2, 2010) by the medical journal The Lancet regarding the retraction of a paper that caused a 12-year international battle over the links between the three-in-one childhood vaccine MMR (measles, mumps, rubella) and autism.

4 Feb 2010

Mandatory flu shot program increases vaccination rate to more than 98% in BJC HealthCare

Making flu shots mandatory in 2008 dramatically increased the vaccination rate among St. Louis-based BJC HealthCare's nearly 26,000 employees to more than 98 percent, according to a report now online in the journal Clinical Infectious Diseases.

4 Feb 2010

Research retraction underscores the safety and efficacy of MMR vaccines

The Lancet, a premier British medical journal, today retracted a study published in 1998 that drew a link between the measles, mumps and rubella (MMR) vaccine and increased incidence of autism.

3 Feb 2010

Study linking autism and vaccines is retracted by medical journal

The Lancet has formally retracted a controversial paper published 12 years ago that purported the measles-mumps-rubella vaccine causes autism.

3 Feb 2010

Sinovac prices public offering at $5.75 per common share

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today that it has priced its public offering of 10,000,000 common shares at $5.75 per common share. Sinovac has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,500,000 common shares on the same terms and conditions.

28 Jan 2010

NewsRx publishes new encyclopedia on vaccines

NewsRx, a 25-year-old publisher and international news organization headquartered in Atlanta, has published a new encyclopedia on vaccines -- Encyclopedia of Vaccines, 2009: An encyK Resource for Parents, Patients & Professionals.

28 Jan 2010

Vaccination for children: Pros and cons

ProCon.org, a nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, created the new website http://vaccines.procon.org to explore the core question "Should any vaccines be required for children?"

23 Jan 2010

Sinovac Biotech announces financial update, new joint ventures and developments

Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, today announced the following recent developments.

21 Jan 2010

SVA plans to sell 8,650,000 common shares in an underwritten public offering

Sinovac Biotech Ltd. ( SVA), a leading China-based vaccine manufacturer, today announced that it plans to sell, subject to market and other conditions, 8,650,000 common shares of the company in an underwritten public offering.

21 Jan 2010

Children’s vaccination coverage rises substantially in U.S.

About three-quarters of U.S. children received recommended vaccinations in 2008, up from about half in 2000, reports a new study from the Centers for Disease Control and Prevention (CDC).

5 Jan 2010

Sinovac Dalian JV to research, develop, produce and commercialize human-use vaccines

Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The JV will research, develop, produce and commercialize human-use vaccines. Sinovac will contribute its expertise and experience in developing and commercializing world-class vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.

25 Nov 2009

Several new vaccines require booster shots to remain effective during a lifetime: Study

Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease prevention. But do all vaccines boost immunity for the same period of time? And, if not, when are additional 'booster shots' needed to keep immunity strong?

24 Nov 2009

Sanofi Pasteur presents Menactra vaccine safety data at the IDSA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, presented Safety of a Quadrivalent (A,C,Y,W-135) Meningococcal Vaccine When Given to Infants with Other Pediatric Vaccines at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) this past weekend.

2 Nov 2009

Women may need smaller dose of H1N1 vaccine

THE emergence of the H1N1 swine flu has added urgency to what has become an annual ritual for millions of Americans: getting a flu shot. The good news is that scientists have developed a vaccine against the H1N1 virus. But it is taking much longer than expected to produce the hundreds of millions of doses the government had planned to distribute. And it is still too soon to know how effective the vaccine will be in preventing swine flu.

31 Oct 2009

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

More teenagers are being vaccinated against human papillomavirus (HPV), meningococcal meningitis and pertussis (whooping cough), though the rates are still too low, according to recently released government data and a panel of experts convened by the National Foundation for Infectious Diseases (NFID).

27 Oct 2009

Merck's sales increases by 2% in third quarter 2009

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.

22 Oct 2009

Research rules out link between MMR vaccines and autism

A new article recently published in the Journal for Specialists in Pediatric Nursing explored vaccination history, vaccine safety monitoring systems in the U.S., and the two most publicized theoretical vaccine-related exposures associated with autism - the vaccine preservative thimerosal and the measles, mumps, and rubella (MMR) vaccine.

9 Oct 2009

H1N1 infected people continue to shed live virus days after the symptoms

ABC News and other outlets are reporting that two studies released on Tuesday suggest that people infected with the H1N1 virus continue to shed virus after the point where current recommendations say they can resume their normal activities.

19 Sep 2009